MedTrace Logo

High Dose Chemo With Autologous BMT for Treatment of Metastatic Breast Cancer

NCT00584428 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 61

Last updated 2019-11-25

No results posted yet for this study

Summary

To evaluate the response rate and the response duration of high dose chemotherapy with autologous bone marrow transplantation as intensification following induction chemotherapy in metastatic breast cancer and to evaluate prospectively the subdivision of patients with metastatic breast cancer according to prognostic groups.

Conditions

  • Breast Neoplasms

Interventions

PROCEDURE

High-Dose Chemo with Autologous BMT

Carboplatin/VP-16/Cytoxan for women 18-59 and Carboplatin/Thiotepa/Cytoxan for women 60-70

Sponsors & Collaborators

  • Stephenson Cancer Center

    collaborator UNKNOWN

  • University of Oklahoma

    lead OTHER

Principal Investigators

  • George Selby, MD · University of Oklahoma

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
1992-06-30
Primary Completion
2002-03-31
Completion
2002-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00584428 on ClinicalTrials.gov